-
Grail, originally founded by Illumina and later spun out as a standalone company, is developing a blood test that aims to detect cancers early. The company has high profile tech and healthcare backers, including Bill Gates, Jeff Bezos, Merck and Johnson & Johnson.3h ago
-
Merger Monday: Gilead buys Immunomedics to boost cancer treatment portfolio. Nvidia purchases Softbank's chip division. Verizon buys Tracfone. PE news from TH Lee and FP.September 14
-
Acquiring Immunomedics will give Gilead an immediate presence in the enormous market for drugs that treat solid tumors such as breast cancer, complementing its medicines like Yescarta that are focused on blood tumors.September 14
-
Pharmaceutical giants including AstraZeneca, GlaxoSmithKline and J&J race to develop a coronavirus vaccine. Blackstone Group and Global Infrastructure Partners reportedly offer to buy railroad operator Kansas City Southern. Roark buys ServiceMaster Brands.September 3
-
Mergers & Acquisitions explores 5 ways the coronavirus is changing dealmaking, as pharmaceutical companies scramble to develop vaccines, diagnostic tools and treatments.August 31
-
For Takeda, the deal brings it close to its goal of $10 billion in asset disposals, as Japan’s largest drugmaker attempts to shed some of the $31 billion in debt that the Shire acquisition added to its balance sheetAugust 24
-
J&J buys Momenta. Sanofi purchases Principia. EQT backs EdgeConneXAugust 21
-
The deal will help J&J's Janssen Pharmaceutical unit broaden its leadership in immune-mediated diseasesAugust 19
-
The deal shows how drug companies like Sanofi need to keep hunting for new drivers of growth even as they race to find vaccines and therapies to try to defeat Covid-19.August 17
-
Formerly named Valeant Pharmaceuticals International, the company became infamous on Wall Street for an acquisition spree as well as raising prices on drugs, a practice that drew scrutiny of its business practices.August 6
